Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in INVEL